Nephros (NEPH) Asset Writedowns and Impairment (2015 - 2026)

Nephros' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $11000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 83.33% year-over-year to $11000.0 in Q1 2026; TTM through Mar 2026 was $73000.0, a 62.56% decrease from a year earlier, with the FY2025 full-year figure at $68000.0, down 74.05% from the prior year.
• Asset Writedowns and Impairment slipped to $11000.0 in Q1 2026 per NEPH's latest filing, from $12000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q3 2022 and bottomed at $6000.0 in Q1 2025.
• The 5-year median for Asset Writedowns and Impairment is $48000.0 (2024), against an average of $135400.0.
• Across the five-year window, Asset Writedowns and Impairment jumped 1396.51% in 2022 and sank 91.78% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $1.3 million in 2022, then plunged by 85.31% to $189000.0 in 2023, then sank by 74.6% to $48000.0 in 2024, then sank by 75.0% to $12000.0 in 2025, then retreated by 8.33% to $11000.0 in 2026.
• Per Business Quant, the three latest NEPH Asset Writedowns and Impairment figures stand at $11000.0 (Q1 2026), $12000.0 (Q4 2025), and $15000.0 (Q3 2025).